Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 25, 2025The Journal of ImmunologyOpen Access

TSC1 as a therapeutic target in mTOR driven triple negative breast cancer 2770

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYunyi XuRARoberto Aguilar

Discussion

Loading...

Member takes

Overview

Bioinformatics analysis identifies TSC1 as a therapeutic target in triple negative breast cancer, suggesting immune evasion impacts prognosis.

Key Points

  • This research aims to identify potential biomarkers and therapeutic targets in triple negative breast cancer (TNBC).
  • Utilized bioinformatics analysis to assess TNBC datasets
  • Identified candidate biomarkers: TSC1, ZFHX4, and CAMTA1
  • Validated TSC1 expression using qPCR and gene sequencing in HCC1937 cell line
  • TSC1 showed significant upregulation in the HCC1937 cell line
  • ZFHX4 and CAMTA1 had negligible expression in validation studies
  • TSC1 is linked to cell growth, metabolism, and immune evasion in the tumor microenvironment

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/692502dc87af00ed34ac2991https://doi.org/10.1093/jimmun/vkaf283.654
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer2025
  2. 2TNFRSF12A Drives Triple-Negative Breast Cancer Progression via Immune Microenvironment Reprogramming and Facilitated Angiogenesis2025
  3. 3Robust CRISPR Screens Identify TPL1 as a Novel Long Noncoding RNA Driving Triple-Negative Breast Cancer Hallmarks2025
  4. 4Resolving tumor microenvironment heterogeneity to forecast immunotherapy response in triple-negative breast cancer through multi-scale analysis2025
  5. 5Identification of tumor associated neutrophils-related genes in triple-negative breast cancer for predicting prognosis and therapeutic response through integrated single-cell analysis2025